Enhancing Post-Operative Analgesia Following Spinal Cord Stimulation Implant: A Comprehensive Evaluation of the Effectiveness of Erector Spinae Plane Block Utilizing Liposomal Bupivacaine

Abstract

Erector spinae plane block (ESPB) is an inter-fascial plane block that provides multi-dermatomal analgesia for treatment of acute pain and chronic neuropathic pain in the trunk. This retrospective case series describes a novel method of treating acute postoperative pain after spinal cord stimulation implant with erector spinae plane block using liposomal bupivacaine. Bilateral erector spinae plane block was administered at L1–L2 intervertebral level in 18 cases prior to performing spinal cord stimulation implant at one interspace above. This study reveals that the block provides effective analgesia as evidenced by low pain scores and less opioid consumption after surgery.

Financial disclosure

M Murphy is a consultant to Medtronic and Relievant. R Teames is a consultant to Pacira, Mindray, Fujifilm and Avanos. Competing disclosures: M Murphy has competing interest with Medtronic, Relievant and Pacira bioscience. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

A Sagir has no conflict of interest to disclose. M Murphy is a consultant to Medtronic and Relievant. R Teames is a consultant to Pacira, Mindray, Fujifilm and Avanos. D Calenda has no conflict of interest to disclose. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The study was determined not to require ethics committee review since it was a retrospective review. The authors state that they have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

Additional information

Funding

M Murphy is a consultant to Medtronic and Relievant. R Teames is a consultant to Pacira, Mindray, Fujifilm and Avanos. Competing disclosures: M Murphy has competing interest with Medtronic, Relievant and Pacira bioscience. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.